European Union · Question · QUESTION_WRITTEN
E-8-2019-000110
Authorisation to place on the market the medicinal product Lynparza (Olaparib) for the first-line treatment of patients with ovarian cancer
Introduced
10 January 2019
Last action
—
Status
answered
Sponsors
—
Subjects
Discovery layer
Source updated
28 February 2019
Official titles
Authentic titles published by the source. The stored canonical title is not replaced.
1 official language
English
Authorisation to place on the market the medicinal product Lynparza (Olaparib) for the first-line treatment of patients with ovarian cancer
Records
Official question E-8-2019-000110 from European Union at European Parliament. Dated 10 January 2019. Status: answered.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
11 official files
Authorisation to place on the market the medicinal product Lynparza (Olaparib) for the first-line treatment of patients with ovarian cancer
Authorisation to place on the market the medicinal product Lynparza (Olaparib) for the first-line treatment of patients with ovarian cancer
QUESTION_WRITTEN · EN · 23 January 2019
Authorisation to place on the market the medicinal product Lynparza (Olaparib) for the first-line treatment of patients with ovarian cancer
QUESTION_WRITTEN · EN · 23 January 2019
Authorisation to place on the market the medicinal product Lynparza (Olaparib) for the first-line treatment of patients with ovarian cancer
QUESTION_WRITTEN · EN · 23 January 2019
Authorisation to place on the market the medicinal product Lynparza (Olaparib) for the first-line treatment of patients with ovarian cancer
QUESTION_WRITTEN · EN · 23 January 2019
Authorisation to place on the market the medicinal product Lynparza (Olaparib) for the first-line treatment of patients with ovarian cancer
QUESTION_WRITTEN · EN · 23 January 2019
Autorizzazione in commercio della specialità medicinale Lynparza, a base di Olaparib, per il trattamento di prima linea di pazienti con carcinoma ovarico
QUESTION_WRITTEN · IT · 4 March 2019
Autorizzazione in commercio della specialità medicinale Lynparza, a base di Olaparib, per il trattamento di prima linea di pazienti con carcinoma ovarico
QUESTION_WRITTEN · IT · 4 March 2019
Answer
QUESTION_WRITTEN_ANSWER · 28 February 2019
Autorizzazione in commercio della specialità medicinale Lynparza, a base di Olaparib, per il trattamento di prima linea di pazienti con carcinoma ovarico
QUESTION_WRITTEN · IT · 23 January 2019
Autorizzazione in commercio della specialità medicinale Lynparza, a base di Olaparib, per il trattamento di prima linea di pazienti con carcinoma ovarico
QUESTION_WRITTEN · IT · 23 January 2019
Autorizzazione in commercio della specialità medicinale Lynparza, a base di Olaparib, per il trattamento di prima linea di pazienti con carcinoma ovarico
QUESTION_WRITTEN · IT · 23 January 2019
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.